Stock HOOK HOOKIPA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Market Closed - Nasdaq
Other stock markets
 01:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
0.8 USD 0.00% Intraday chart for HOOKIPA Pharma Inc. -12.84% -1.23%
25/04 Transcript : HOOKIPA Pharma Inc. - Special Call
25/04 HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
GL
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
GL
HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
GL
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
AQ
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
GL
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
GL
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
AQ
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
AQ
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
AQ
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
GL
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
GL
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
AQ
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
GL
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
AQ
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HOOK Stock
  4. News HOOKIPA Pharma Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW